Medidata AI Showcases Advances In CAR-T Research At The 65th American Society Of Hematology Annual Meeting

Medidata Solutions showcased three research posters at the 65th American Society of Hematology (ASH) annual meeting, emphasizing the impact of academic-industry collaborations on CAR-T (chimeric antigen receptor T-cell) therapy. The research, part of the newly-launched Medidata Research Alliance, explores the connection between phosphorus disruption and neurotoxicity symptoms in CD19-targeted CAR T-cell therapy, proposing phosphorus monitoring as a potential biomarker for immune effector cell-associated neurotoxicity syndrome (ICANS). Another study focused on predicting severe cytokine release syndrome (CRS) associated with T-cell engaging therapies, utilizing patient-level data from past clinical trials. The third poster presented a machine learning-based decision tree for managing ICANS in CAR-T therapy, aiming to assist physicians in predicting and grading the severity of neurotoxicity events.

These findings demonstrate the collaborative efforts to enhance understanding and safety in the evolving field of CAR-T and immunotherapy.